Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib cream in atopic dermatitis with sleep disturbance
NCT05696392Phase 4Terminated
- Sponsor
- Incyte
- Start
- Mar 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ruxolitinib cream in atopic dermatitis (AD), sponsored by Incyte. Started Mar 2023; status: terminated.
02
Drugs
ruxolitinib cream
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05696392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05696392.